



GOUR MEDICAL SA announced today that it has entered into an exclusive license agreement with IDEXX Laboratories, Inc. to continue the development of a recombinant monoclonal antibody for therapeutic use: anti-IgE chimeric antibody for the treatment of canine allergy.

December 21st, 2015

ZUG, Switzerland - Gour Medical SA, a veterinary biomedical company, announced today the signing of an agreement with IDEXX Laboratories, Inc. for the development of a therapeutic recombinant monoclonal antibody for use in dogs.

Gour plans to continue the development of a therapeutic recombinant dog-specific monoclonal antibody and to launch it in the market. A first product is under development for the treatment and prevention of atopic dermatitis in dogs, a substantial unmet medical need.

As a first step, Gour plans to conduct a proof-of-concept study to establish the efficacy of the dog specific recombinant antibody in this indication.

About Gour Medical SA

Gour Medical SA, founded in 2014, is a Swiss based veterinary biomedical company, leveraging the advances in human research and applying them to medical solutions for companion animals. Integrated and innovative therapeutic solutions developed by Gour address companion animals' unmet medical needs by treating or preventing significant companion animal health issues.

Gour has already signed several cooperation agreements with world renowned companies and laboratories for the development and commercialization of various animal healthcare products.

Contacts

Gour Medical SA
Serge Goldner, CEO
+41 435 08 00 72 contact@gour-medical.com

For more information on Gour, please visit www.gour-medical.com

Source: Gour Medical SA